National Virus Vector Laboratory //
Selected Publications

  1. Kivelä, Huusko, Gurzeler, Laine, Dijkstra, Dragneva, Andersen, Moestrup,  Ylä-Herttuala. High Plasma Lipid Levels Reduce Efficacy of Adenovirus-Mediated Gene Therapy. Sci Rep. 7(1):386, 2017. doi: 10.1038/s41598-017-00376-5
  2. Hassinen, Kivelä, Hedman, Saraste, Knuuti, Hartikainen, Ylä-Herttuala. Intramyocardial gene therapy directed to hibernating heart muscle using a combination of electromechanical mapping and positron emission tomography. Human Gene Therapy, 27(10): 830-834, 2016. doi:10.1089/hum.2016.131
  3. Babu, Devi, Mäkinen, Kaikkonen,  Lesch, Junttila, Laiho, Ghimire, Gyenesei, Ylä-Herttuala. Genome-wide promoter methylation analysis reveals macrophage skewing during impaired vascular growth in ischemic muscles of hyperlipidemic and type 2 diabetic mice. Circulation Research, 117:289-299, 2015. doi: 10.1161/CIRCRESAHA.115.306424
  4. Aavik, Lumivuori, Leppänen, Wirth, Häkkinen, Bräsen, Beschorner, Zeller, Braspenning, van Criekinge, Mäkinen, Ylä-Herttuala. Global DNA methylation analysis of human atherosclerotic plaques reveals extensive genomic hypomethylation and reactivation at imprinted locus 14q32 involving induction of a miRNA cluster.  Eur. Heart J. 36:993-1000, 2015. doi: 10.1093/eurheartj/ehu437
  5. Kaikkonen, Niskanen, Romanoski, Kansanen, Kivelä, Laitalainen, Heinz, Benner, Glass, Ylä-Herttuala. Control of VEGF-A transcriptional programs by pausing and genomic compartmentalization. Nucl. Acids Res. 42:12570-12584, 2014. doi:10.1093/nar/gku1036
  6. Turunen, Husso, Musthafa, Laidinen, Dragneva, Laham-Karam, Honkanen, Paakinaho, Laakkonen, Gao, Vihinen-Ranta, Liimatainen, Ylä-Herttuala. Epigenetic Upregulation of Endogenous VEGF-A Reduces Myocardial Infarct Size in Mice. PLoS One 9; e89979, 2014. doi:10.1371/journal.pone.0089979
  7. Westphal, Ylä-Herttuala, Martin, Warnke, Menei, Eckland, Kinley, Kay, Ram, ASPECT Study Group. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol. 14; 823-833, 2013. doi: 10.1016/S1470-2045(13)70274-2
  8. Schenkwein, Turkki, Ahlroth, Timonen, Airenne, Ylä-Herttuala. rDNA-directed integration by an HIV-1 integrase – I-PpoI fusion protein. Nucl. Acids Res. 41; e61, 2013. doi: 10.1093/nar/gks1438
  9. Korpisalo, Hytönen, Laitinen, Laidinen, Parviainen, Karvinen, Siponen, Marjomäki, Vajanto, Rissanen, Ylä-Herttuala. Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side-effects of angiogenic gene therapy. Eur Heart J. 32; 1664-1672, 2011. doi:10.1093/eurheartj/ehq433
  10. Hagberg, Falkewall, Wang, Klar, Larsson, Huusko, Nilsson, van Meeteren, Samen, Lu, Vanwildemeersch, Klar, Genove, Pietras, Stone-Elander, Claesson-Welsh, Ylä-Herttuala, Lindahl, Eriksson. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464; 917-921, 2010. doi: 10.1038/nature08945
  11. Turunen, Lehtola, Heinonen, Assefa, Korpisalo, Girnary, Glass, Väisänen, Ylä-Herttuala. Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism. A novel example of epigenetherapy. Circ. Res. 105; 604-609, 2009. doi:10.1161/CIRCRESAHA.109.200774
  12. Lähteenvuo, Lähteenvuo, Kivelä, Rosenlew, Falkevall, Klar, Heikura, Rissanen, Vähäkangas, Korpisalo, Enholm, Carmeliet, Alitalo, Eriksson, Ylä-Herttuala. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1 and Neuropilin receptor-1 dependent mechanisms. Circulation 119; 845-856, 2009. doi: 10.1161/CIRCULATIONAHA.108.816454